05.03.2015
Vita 34 AG DE000A0BL849
DGAP-News: Vita 34 AG Publishes Preliminary Figures for Fiscal Year 2014
DGAP-News: Vita 34 AG / Key word(s): Preliminary Results
Vita 34 AG Publishes Preliminary Figures for Fiscal Year 2014
05.03.2015 / 07:31
---------------------------------------------------------------------
Vita 34 AG Publishes Preliminary Figures for Fiscal Year 2014
- Total operating revenue higher than prior year
- High level of profitability: EBITDA margin continues to be strong at
20.1 percent
- Earnings per share increased by 28.6 percent
Leipzig, 05 March 2015 - Vita 34 AG (WKN A0BL84), a pioneer in the storage
of stem cells from umbilical cord blood and tissue, and a specialist in
cryo-preservation improved the group key figures in fiscal year 2014 as
compared with the prior year, and fulfilled the prognosis for fiscal year
2014 that had been updated in Q3.
According to preliminary figures, the total operating revenue increased to
EUR 15.2 million in fiscal year 2014 and was 2.7 percent higher than the
prior year's value of EUR 14.8 million. Sales revenues increased to EUR
13.8 million following EUR 13.6 million in fiscal year 2013. The growth in
revenues can be mainly attributed to the increased number of newly stored
stem cell deposits of umbilical cord blood and tissue. In the reporting
period they increased by some 2.9 percent as compared with the prior year
to 7,378 stem cell deposits. EBITDA improved from EUR 2.7 million in fiscal
year 2013 to EUR 2.8 million in the reporting period. This is equivalent to
a high EBITDA margin of 20.1 percent (2013: 19.6 percent). The operating
profit (EBIT) increased as well and amounted to EUR 1.7 million in fiscal
year 2014, following EUR 1.5 million the prior year, corresponding to an
EBIT margin of 12.3 percent (2013: 10.8 percent). The period result
improved to EUR 1.0 million following EUR 0.8 million in the 2013 reference
period. The earnings per share, based on the period result attributable to
holders of common stock of the parent company, increased by 28.6 percent to
EUR 0.36 (2013: EUR 0.28).
"We set decisive measures in fiscal year 2014 and consider ourselves to be
on the right path. The EBITDA margin of 20.1 percent underscores the
profitability of our business activities," commented Dr. André Gerth, CEO
of Vita 34 AG. "The key to the positive business development lies in the
consistent implementation of our growth strategy. We have achieved
significant milestones with the acquisition of the business of Austrian
market leader Vivocell as of January 2, 2015 as an asset deal, the
extension of cooperations with partners in other countries, as well as with
the product launch of VitaPlusNabelschnur [VitaPlusCord] in Europe in
fiscal year 2014."
In the first months of 2015, Vita 34 has followed the prior year's lead and
entered into a cooperation agreement with the Baltic stem cell bank AS
"Imunolita." With the associated market entry in the Baltic states, Vita 34
is now active in 20 countries apart from Germany. In the current fiscal
year Vita 34 expects a total operating revenue and an EBITDA at the level
of 2014.
The complete Annual Report 2014 will be available for download as of March
26, 2015 on the company website at www.vita34group.com in the "Investor
Relations" section.
Company Profile
Vita 34 was founded in 1997 as the first private umbilical cord blood bank
in Europe and, as a complete provider, offers collection logistics,
preparation and storage of umbilical cord blood and cord tissue. The basis
for its successful work is an outstanding position in the technological
segment of cryo-preservation. Here, cells and tissue are preserved alive at
some -190ºC for long periods of time, and can be used if needed in the
context of medical treatment. More than 123,000 families are already taking
advantage of this offering and have provided with a stem cell deposit at
Vita 34.
---------------------------------------------------------------------
05.03.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: [email protected]
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
330019 05.03.2015
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Vita 34 AG ISIN: DE000A0BL849 können Sie bei EQS abrufen
Biotechnologie , A0BL84 , V3V , XETR:V3V